Small Molecule Tyrosine Kinase Inhibitors Approved for Systemic Therapy of Advanced Hepatocellular Carcinoma: Recent Advances and Future Perspectives.
Jianzhong Liu,Shuai Xia,Baoyi Zhang,Dina Mostafa Mohammed,Xiangliang Yang,Yanhong Zhu,Xinnong Jiang
DOI: https://doi.org/10.1007/s12672-024-01110-0
2024-01-01
Discover Oncology
Abstract:Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of liver cancer. More than half of the HCC patients are diagnosed at an advanced stage and often require systemic therapy. Dysregulation of the activity of receptor tyrosine kinases (RTKs) is involved in the development and progress of HCC, RTKs are therefore the potential targets for systemic therapy of advanced HCC (aHCC). Currently, a total of six small molecule tyrosine kinase inhibitors (TKIs) have been approved for aHCC, including first-line sorafenib, lenvatinib, and donafenib, and second-line regorafenib, cabozantinib, and apatinib. These TKIs improved patients survival, which are associated with disease stage, etiology, liver function, tumor burden, baseline levels of alpha-fetoprotein, and treatment history. This review focuses on the clinical outcomes of these TKIs in key clinical trials, retrospective and real-world studies and discusses the future perspectives of TKIs for aHCC, with an aim to provide up-to-date evidence for decision-making in the treatment of aHCC.